TFPI Protein & Antibody

 Tissue Factor Pathway Inhibitor

TFPI Products

TFPI Protein, Recombinant

Molecule	Species	Description	Cat. No
TFPI	Human	TFPI Protein, Recombinant	10564-H08H
TFPI	Mouse	TFPI Protein, Recombinant	50131-M08H

 10564-H08H: IC₅₀ value   <  0.4 nM.Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 (Anaspec, Catalog#27114 )

 50131-M08H: IC₅₀ value   <  0.15 nM.Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca-RPKPVE-Nval-WRK(Dnp)-NH2 ( Anaspec, Catalog # 27114 )

TFPI Antibody

Molecule	Application	Description	Cat. No
Human TFPI	WB, ELISA	Mouse Monoclonal Antibody	10564-MM01
Human TFPI	ELISA	Rabbit Monoclonal Antibody	10564-R003
Human TFPI	WB	Rabbit Monoclonal Antibody	10564-R006
Human TFPI	WB, ELISA	Rabbit Polyclonal Antibody	10564-RP01
Human TFPI	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)	10564-RP02
Mouse TFPI	WB, ELISA	Rabbit Polyclonal Antibody	50131-RP01

TFPI cDNA Clone

Molecule	Species	Description	Cat. No
TFPI	Human	Homo sapiens TFPI cDNA Clone	HG10564-M
TFPI	Mouse	Mus musculus TFPI cDNA Clone	MG50131-M

TFPI Related Areas

Enzyme>>Protease & Regulator>>Serine Protease & Regulator>>TFPI

Immunology>>Innate Immunity>>Coagulation>>TFPI

Cardiovascular>>Coagulation>>TFPI

TFPI Alternative Names

TFPI, TFPI1, TFI, EPI, LACI [Homo sapiens]

Tfpi, EPI, LACI, RP23-202K13.2, A630013F22Rik, AW552122 [Mus musculus]

TFPI Related Products

Protein Products

Molecule	Species	Description
TFPI2	Human	TFPI2 Protein, Recombinant
TFPI2	Mouse	TFPI2 Protein, Recombinant

Antibody Products

Molecule	Application	Description
Human TFPI2	ELISA	Mouse Monoclonal Antibody
Human TFPI2	WB, ELISA	Rabbit Polyclonal Antibody
Human TFPI2	WB, ELISA	Rabbit Polyclonal Antibody (Antigen Affinity Purified)

cDNA Clone Products

Molecule	Species	Description
TFPI2	Human	Homo sapiens TFPI2 cDNA Clone(NM_006528.2)

TFPI Background

Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of TF coagulant and signaling activities. It is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. With its Kunitz domains, TFPI exhibits significant homology with human inter-alpha-trypson inhibitor and bovin basic pancreatic trypsin inhibitor. TFPI is the natural inhibitor of TF coagulant and signaling activities. The importance of TFPI in the regulation of blood coagulation is emphasized by how its activity is modulated in human disease. In a factor (F) Xa-dependent feedback system, TFPI binds directly and inhibits the TF-FVII/FVIIa complex. Normally, TFPI exists in plasma both as a full-length molecule and as variably carboxy-terminal truncated forms. TFPI also circulates in complex with plasma lipoproteins. The levels and the dual inhibitor effect of TFPI on FXa and TF-FVII/FVIIa complex offers insight into the mechanisms of various pathological conditions triggered by TF. TFPI may play an important role in modulating TF-induced thrombogenesis and it may also provide a unique therapeutic approach for prophylaxis and/or treatment of various diseases. In addition, Studies have shown that TFPI exhibits antiangiogenic and antimetastatic effects in vitro and in vivo. In animal models of experimental metastasis, both circulating and tumor cell-associated TFPI are shown to significantly reduce tumor cell-induced coagulation activation and lung metastasis. Heparins and heparin derivatives, which induce the release of TFPI from the vascular endothelium, also exhibit antitumor effects, and TFPI may contribute significantly to those effects.

TFPI Related Studies

1. Lwaleed BA, et al. (2006) Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 208(3): 327-39.
2. Amirkhosravi A, et al. (2007) The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost. 33(7): 643-52.
3. Maroney SA, et al. (2008) Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 38(1): 9-14.